JP2574176B2 - Yellow solid color - Google Patents
Yellow solid colorInfo
- Publication number
- JP2574176B2 JP2574176B2 JP1032373A JP3237389A JP2574176B2 JP 2574176 B2 JP2574176 B2 JP 2574176B2 JP 1032373 A JP1032373 A JP 1032373A JP 3237389 A JP3237389 A JP 3237389A JP 2574176 B2 JP2574176 B2 JP 2574176B2
- Authority
- JP
- Japan
- Prior art keywords
- colored
- coloring
- substance
- tablet
- riboflavin butyrate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000007787 solid Substances 0.000 title claims description 19
- MJNIWUJSIGSWKK-BBANNHEPSA-N Riboflavin butyrate Chemical compound CCCC(=O)OC[C@@H](OC(=O)CCC)[C@@H](OC(=O)CCC)[C@@H](OC(=O)CCC)CN1C2=CC(C)=C(C)C=C2N=C2C1=NC(=O)NC2=O MJNIWUJSIGSWKK-BBANNHEPSA-N 0.000 claims description 39
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 33
- 238000004040 coloring Methods 0.000 claims description 31
- 239000003814 drug Substances 0.000 claims description 26
- 239000000725 suspension Substances 0.000 claims description 26
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 25
- 239000000126 substance Substances 0.000 claims description 19
- 229940079593 drug Drugs 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 15
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 13
- 239000000463 material Substances 0.000 claims description 13
- 239000002775 capsule Substances 0.000 claims description 10
- 150000002148 esters Chemical class 0.000 claims description 7
- 235000010323 ascorbic acid Nutrition 0.000 claims description 6
- 239000011668 ascorbic acid Substances 0.000 claims description 6
- 229960005070 ascorbic acid Drugs 0.000 claims description 6
- 235000010378 sodium ascorbate Nutrition 0.000 claims description 4
- 229960005055 sodium ascorbate Drugs 0.000 claims description 4
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 claims description 4
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 claims description 4
- 238000001291 vacuum drying Methods 0.000 claims description 2
- 239000003826 tablet Substances 0.000 description 35
- 239000008187 granular material Substances 0.000 description 24
- 239000000843 powder Substances 0.000 description 17
- 239000000047 product Substances 0.000 description 12
- 239000007788 liquid Substances 0.000 description 11
- 239000008298 dragée Substances 0.000 description 10
- 235000013305 food Nutrition 0.000 description 10
- 239000007940 sugar coated tablet Substances 0.000 description 9
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 8
- 229920002472 Starch Polymers 0.000 description 8
- 239000008107 starch Substances 0.000 description 8
- 235000019698 starch Nutrition 0.000 description 8
- 235000005979 Citrus limon Nutrition 0.000 description 7
- 244000248349 Citrus limon Species 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 238000005469 granulation Methods 0.000 description 6
- 230000003179 granulation Effects 0.000 description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
- 239000008101 lactose Substances 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 229960002477 riboflavin Drugs 0.000 description 4
- 235000019192 riboflavin Nutrition 0.000 description 4
- 239000002151 riboflavin Substances 0.000 description 4
- -1 riboflavin butyrate ester Chemical class 0.000 description 4
- 238000005507 spraying Methods 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 235000010724 Wisteria floribunda Nutrition 0.000 description 3
- 235000019658 bitter taste Nutrition 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 239000007902 hard capsule Substances 0.000 description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- 229920001218 Pullulan Polymers 0.000 description 2
- 239000004373 Pullulan Substances 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- OIQPTROHQCGFEF-UHFFFAOYSA-L chembl1371409 Chemical compound [Na+].[Na+].OC1=CC=C2C=C(S([O-])(=O)=O)C=CC2=C1N=NC1=CC=C(S([O-])(=O)=O)C=C1 OIQPTROHQCGFEF-UHFFFAOYSA-L 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 235000013373 food additive Nutrition 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 238000000634 powder X-ray diffraction Methods 0.000 description 2
- 235000019423 pullulan Nutrition 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 238000009495 sugar coating Methods 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 2
- FMCGSUUBYTWNDP-ONGXEEELSA-N (1R,2S)-2-(dimethylamino)-1-phenyl-1-propanol Chemical compound CN(C)[C@@H](C)[C@H](O)C1=CC=CC=C1 FMCGSUUBYTWNDP-ONGXEEELSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- YQSHYGCCYVPRDI-UHFFFAOYSA-N (4-propan-2-ylphenyl)methanamine Chemical compound CC(C)C1=CC=C(CN)C=C1 YQSHYGCCYVPRDI-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N Alumina Chemical compound [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- FMCGSUUBYTWNDP-UHFFFAOYSA-N N-Methylephedrine Natural products CN(C)C(C)C(O)C1=CC=CC=C1 FMCGSUUBYTWNDP-UHFFFAOYSA-N 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229940024545 aluminum hydroxide Drugs 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- QFFVPLLCYGOFPU-UHFFFAOYSA-N barium chromate Chemical compound [Ba+2].[O-][Cr]([O-])(=O)=O QFFVPLLCYGOFPU-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 235000001465 calcium Nutrition 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 235000010376 calcium ascorbate Nutrition 0.000 description 1
- 229940047036 calcium ascorbate Drugs 0.000 description 1
- 239000011692 calcium ascorbate Substances 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- BLORRZQTHNGFTI-ZZMNMWMASA-L calcium-L-ascorbate Chemical compound [Ca+2].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] BLORRZQTHNGFTI-ZZMNMWMASA-L 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- FDJOLVPMNUYSCM-UVKKECPRSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7, Chemical compound [Co+3].N#[C-].C1([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)[N-]\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O FDJOLVPMNUYSCM-UVKKECPRSA-L 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 229960003782 dextromethorphan hydrobromide Drugs 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000005562 fading Methods 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000000989 food dye Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 235000019223 lemon-lime Nutrition 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- 229960000869 magnesium oxide Drugs 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000003264 margarine Substances 0.000 description 1
- 235000013310 margarine Nutrition 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229960002221 methylephedrine Drugs 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 1
- 229960004172 pyridoxine hydrochloride Drugs 0.000 description 1
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 1
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000009492 tablet coating Methods 0.000 description 1
- 239000002700 tablet coating Substances 0.000 description 1
- UIERGBJEBXXIGO-UHFFFAOYSA-N thiamine mononitrate Chemical compound [O-][N+]([O-])=O.CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N UIERGBJEBXXIGO-UHFFFAOYSA-N 0.000 description 1
- UJMBCXLDXJUMFB-UHFFFAOYSA-K trisodium;5-oxo-1-(4-sulfonatophenyl)-4-[(4-sulfonatophenyl)diazenyl]-4h-pyrazole-3-carboxylate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)C1=NN(C=2C=CC(=CC=2)S([O-])(=O)=O)C(=O)C1N=NC1=CC=C(S([O-])(=O)=O)C=C1 UJMBCXLDXJUMFB-UHFFFAOYSA-K 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 229910052724 xenon Inorganic materials 0.000 description 1
- FHNFHKCVQCLJFQ-UHFFFAOYSA-N xenon atom Chemical compound [Xe] FHNFHKCVQCLJFQ-UHFFFAOYSA-N 0.000 description 1
- 239000001060 yellow colorant Substances 0.000 description 1
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicinal Preparation (AREA)
Description
【発明の詳細な説明】 産業上の利用分野 本発明は、C型のリボフラビン酪酸エステルを色素と
して用い、食品あるいは医薬品などの分野における被着
色物に着色を施すことにより得られる黄色固体着色物に
関する。Description: BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a yellow solid colored material obtained by using a C-type riboflavin butyrate ester as a pigment and coloring an object to be colored in the field of food or medicine. .
従来の技術および発明が解決しようとする課題 食品・医薬品などの分野では固形状製品が数多く見受
けられる。これらは商品としてのイメージの向上や薬剤
識別のため、通常着色が施こされている。2. Description of the Related Art Problems to be solved by the conventional technology and the invention In the fields of food and medicine, there are many solid products. These are usually colored to improve the image as a product or to identify the medicine.
一般に、食品あるいは医薬品を黄色に着色する場合、
タール系色素の食用黄色4号,食用黄色4号アルミニウ
ムレーキ(第5版食品添加物),黄色ベンガラ(局方外
成分規格;1986年版),更にはリボフラビン(特公昭46
−26989,特公昭61−3224号公報),リボフラビン酪酸エ
ステル等が用いられている。Generally, when coloring food or medicine in yellow,
Food dye No. 4 of food tar color, food yellow No. 4 aluminum lake (Fifth edition food additive), yellow bengalara (Extra-European component standard; 1986 version), and riboflavin (Tokoku 46)
26989, JP-B-61-3224) and riboflavin butyrate.
また、天然色素としては、粉末サンエローNo.3(カロ
チノイド系;三栄化学),粉末サンエローNo.2(フラボ
ノイド系;三栄化学;特公昭50−148562)等がある。Examples of natural pigments include powdered sun yellow No. 3 (carotenoid type; San-ei Chemical) and powdered sun yellow No. 2 (flavonoid type; San-ei chemical; Japanese Patent Publication No. 50-148562).
このうち、リボフラビンは乳製品や小麦加工製品等食
品の黄色着色剤や栄養強化剤として使われているが、ア
ルカリ条件下では光に対して弱く、褪色しやすい傾向が
ある。Of these, riboflavin is used as a yellow colorant and a nutritional enhancer for foods such as dairy products and processed wheat products, but tends to be faint to light under alkaline conditions and easily discolored.
また、顆粒,錠剤等の固形製剤の着色にリボフラビン
を使用すると服用時にリボフラビン自体の苦味を感じる
上に色調自体も、レモン系の黄色というよりも黄橙色系
になるという欠点があった。In addition, when riboflavin is used for coloring solid preparations such as granules and tablets, there is a disadvantage that the riboflavin itself feels bitterness when taken, and the color itself becomes yellow-orange rather than lemon-yellow.
また、リボフラビン酪酸エステルは、苦味はないが脂
溶性であるため、専らマーガリン,チーズ,クリームな
ど油性食品用に使われているに過ぎない。Further, riboflavin butyrate has no bitterness but is fat-soluble, and is therefore only used exclusively for oily foods such as margarine, cheese and cream.
しかも、このエステルの場合にも、黄橙味を帯びレモ
ン系の明るい鮮明な黄色を出すのは困難であった。In addition, even with this ester, it was difficult to produce a bright, yellowish yellowish orange lemon.
課題を解決するための手段 本発明者らは、安全性が最も高いといわれているリボ
フラビン酪酸エステルを色素として用い、これを食品・
医薬品などの着色に適用することについて鋭意検討の結
果、A型、B型およびC型のリボフラビン酪酸エステル
のうち、特に、C型が、食品・医薬品などの着色に極め
て有効であって、しかも得られた着色物には色むらがな
く、レモン系の明るい鮮やかな黄色を呈すことを見い出
し、更に検討の結果、本発明を完成した。Means for Solving the Problems The present inventors have used riboflavin butyrate, which is said to be the most safe, as a dye, and
As a result of intensive studies on the application to coloring of pharmaceuticals, etc., among the riboflavin butyrate esters of type A, B, and C, in particular, type C is extremely effective for coloring foods and pharmaceuticals, and is obtained. The colorants obtained were found to have no color unevenness and to exhibit a lemon-based bright bright yellow, and as a result of further studies, the present invention was completed.
すなわち、本発明は(i)薬剤成分を含有する被着色
物をC型のリボフラビン酪酸エステルで着色してなる黄
色固体着色物、(ii)カプセルまたは錠剤である被着色
物をC型のリボフラビン酪酸エステルで着色してなる黄
色固体着色物および(iii)粉末状ないし粒状の薬剤成
分あるいはカプセルまたは錠剤である被着色物をC型の
リボフラビン酪酸エステルで着色することを特徴とする
着色方法である。That is, the present invention relates to (i) a yellow solid color product obtained by coloring a substance containing a drug component with a C-type riboflavin butyrate, and (ii) a C-type riboflavin butyrate which is a capsule or tablet. A coloring method characterized by coloring a yellow solid colored substance colored with an ester and (iii) a powdered or granular drug component or a substance to be colored such as a capsule or a tablet with C-type riboflavin butyrate.
本発明で用いるC型のリボフラビン酪酸エステルは
“薬学雑誌,108(1),39-43(1988)”に記載されて
いる。The C-type riboflavin butyrate used in the present invention is described in Pharmaceutical Journal, 108 (1), 39-43 (1988).
前記文献には、A型、B型、C型の3種のリボフラビ
ン酪酸エステルが報告されており、それぞれ橙赤色、カ
ーキ色、黄色の固体であり、結晶系が異なることが知ら
れている。The literature reports three types of riboflavin butyrate esters of type A, type B, and type C, which are orange-red, khaki, and yellow solids, respectively, and are known to have different crystal systems.
このうち、C型のリボフラビン酪酸エステルはA型の
リボフラビン酪酸エステルのメタノール溶液を水中へ激
しく攪拌しながら注ぐと生じる。Among them, the C-type riboflavin butyrate is formed by pouring a methanol solution of the A-type riboflavin butyrate into water with vigorous stirring.
本発明においては、通常市販されているA型のリボフ
ラビン酪酸エステルのエタノール溶液を水に分散させ、
C型のリボフラビン酪酸エステルを得た。In the present invention, a commercially available ethanol solution of Form A riboflavin butyrate is dispersed in water,
C-type riboflavin butyrate was obtained.
このC型のリボフラビン酪酸エステルを食品・医薬品
などの着色に適用したところ、意外にも従来にはなかっ
た鮮やかな明るいレモン系の黄色に着色されることが判
明した。When this C-type riboflavin butyrate was applied to coloring of foods, pharmaceuticals, etc., it was found that it was unexpectedly bright and bright lemon-based yellow which had never existed before.
また、本発明で使用するリボフラビン酪酸エステルは
リボフラビンテトラブチレートを意味し、天然色素であ
り、このものは局方外成分規格(1986年版),食品添加
物公定書(第5版)に収載されている。The riboflavin butyrate used in the present invention means riboflavin tetrabutyrate, which is a natural colorant, and is described in the Standards for Extraterrestrial Components (1986 edition) and the Official Standards for Food Additives (5th Edition). ing.
本発明ではこのエステルをまずエタノールに溶解して
溶液としたのち、これを水に分散させて懸濁液とし、こ
のものを着色液、さらには造粒液として用いる。In the present invention, this ester is first dissolved in ethanol to form a solution, which is then dispersed in water to form a suspension, which is used as a coloring liquid and further as a granulating liquid.
または、該懸濁液をろ過し、真空乾燥して粉末状にし
たものを用いることもできる。Alternatively, the suspension may be filtered and vacuum-dried to form a powder.
その他、適用する被着色物の性状に対応して、種々の
形態を選ぶこともできる。In addition, various forms can be selected according to the properties of the material to be applied.
懸濁液として用いる場合、懸濁液は通常、エステルの
エタノール溶液を水に投入して攪拌下分散させることに
より得られる。また、逆にエステルのエタノール溶液に
水を攪拌下投入して分散させる方法でもよい。When used as a suspension, the suspension is usually obtained by adding an ethanol solution of the ester to water and dispersing the mixture under stirring. Conversely, a method in which water is added to an ethanol solution of the ester with stirring and dispersed may be used.
分散温度は通常、室温下で行なわれる。 The dispersion temperature is usually performed at room temperature.
エタノール溶液中のエステルの濃度は、ほぼ1〜70重
量%になるように調節する。The concentration of the ester in the ethanol solution is adjusted to be approximately 1 to 70% by weight.
懸濁液は水100重量部に対してエタノール溶液ほぼ100
重量部以下、好ましくは40重量部以下が用いられる。The suspension is almost 100 parts by weight of ethanol solution per 100 parts by weight of water.
Not more than 40 parts by weight, preferably not more than 40 parts by weight is used.
次いで、このようにして調製された懸濁液を使って、
被着色物に着色が施すことができる。Then, using the suspension thus prepared,
Coloring can be applied to the object to be colored.
着色するには、最も普通には懸濁液を被着色物に添加
して均一に混合する方法や懸濁液を被着色物に均一にス
プレーするなどの方法を採ることができる。For coloring, most commonly, a method of adding a suspension to a material to be colored and mixing uniformly, or a method of uniformly spraying the suspension on the material to be colored can be employed.
本発明の黄色固体着色物をC型のリボフラビン酪酸エ
ステルの懸濁液を用いて製造する場合、C型のリボフラ
ビン酪酸エステル懸濁液の使用量は被着色物の約0.001
〜10重量%、好ましくは0.001〜5重量%である。When the yellow solid color product of the present invention is produced using a suspension of riboflavin butyrate ester of type C, the amount of the suspension of riboflavin butyrate ester of type C is about 0.001% of the material to be colored.
-10% by weight, preferably 0.001-5% by weight.
0.001重量%未満では着色の点で不充分であると共に
褪色が起りやすくなることがある。If the amount is less than 0.001% by weight, the coloring may be insufficient, and fading may easily occur.
また、10重量%を超えると、懸濁液、特に水の量が多
くなり、造粒に支障をきたしたり、作業時間が長くなり
好ましくないことある。On the other hand, if the content exceeds 10% by weight, the amount of the suspension, particularly water, becomes large, which may hinder granulation or increase the working time, which may be undesirable.
C型のリボフラビン酪酸エステル懸濁液の使用量は、
懸濁液調製時のエタノール溶液の濃度、このエタノール
を水に分散させる時の水の使用量、造粒法、被着色物の
性状などによって左右され、一概に特定できるものでは
なく、適宜決定すればよい。The amount of the C-type riboflavin butyrate suspension used is:
It depends on the concentration of the ethanol solution at the time of preparing the suspension, the amount of water used when dispersing this ethanol in water, the granulation method, the properties of the material to be colored, and the like. I just need.
また、被着色物が粉末状のものである場合には、この
粉末を造粒しながら着色せしめることができる。When the object to be colored is in the form of a powder, the powder can be colored while being granulated.
造粒には、湿式攪拌造粒機(例えば、ポニーミキサ
ー;井上製作所(株)製),バーチカルグラニュレー
タ,富士産業(株)製)や流動層造粒装置(たとえばグ
ラット;西独グラット社製,フローコーター;フロイン
ト産業(株)製,エアロマチック;富士産業(株)製)
などを用いることができる。Granulation includes a wet stirring granulator (eg, a pony mixer; manufactured by Inoue Seisakusho Co., Ltd.), a vertical granulator, manufactured by Fuji Sangyo Co., Ltd.) and a fluidized bed granulator (eg, Glatt; manufactured by West German Glatt Co., Ltd.). Flow coater; Freund Sangyo Co., Ltd., Aeromatic; Fuji Sangyo Co., Ltd.)
Etc. can be used.
この場合、本発明の懸濁液には、適宜従来から汎用さ
れている結合剤(例えばデンプン糊,ヒドロキシプロピ
ルセルロース,ヒドロキシプロピルメチルセルロース,
メチルセルロース,カルボキシメチルセルロースナトリ
ウム,ポリビニルピロリドン,ゼラチン,プルラン,シ
ョ糖)などを加えておいてもよい。In this case, the suspension of the present invention may be appropriately added to a conventionally used binder (for example, starch paste, hydroxypropylcellulose, hydroxypropylmethylcellulose,
Methylcellulose, sodium carboxymethylcellulose, polyvinylpyrrolidone, gelatin, pullulan, sucrose) and the like.
また、これらの結合剤溶液を懸濁液と一緒に被着色物
に添加してもよい。In addition, these binder solutions may be added to the material to be colored together with the suspension.
被着色物として、粉体あるいは粒状物(10μm〜1mm
の粒径)のものが用いられることが多い。Powder or granular material (10 μm to 1 mm
Are often used.
粉体を造粒しながら着色したときは、黄色に着色した
造粒物が得られる。When the powder is colored while being granulated, a granule colored yellow is obtained.
このものは、適宜整粒して種々の粒度の粒状物にする
ことができる。This product can be appropriately sized to obtain granules having various particle sizes.
例えば、カプセル剤のシェルのように、被着色物がそ
の製造工程中、融解され液状である場合は、懸濁液をそ
の液状物に添加して製造することもできる。For example, when the material to be colored is melted and in a liquid state during the manufacturing process, such as a shell of a capsule, a suspension can be added to the liquid to manufacture the material.
粉末状にしたC型のリボフラビン酪酸エステルを使用
する場合、例えば、造粒する際の結合液に直接添加する
ことや被着色物に混合して使用することもできる。When the powdered C-type riboflavin butyrate is used, for example, it can be directly added to a binding solution at the time of granulation or mixed with a material to be colored.
また、製造工程中に液状となるものについては、その
液状物に直接添加して、製造することもできる。In addition, those which become liquid during the manufacturing process can be directly added to the liquid to be manufactured.
この粉末状C型のリボフラビン酪酸エステルの使用量
は、製造する目的物によって適宜決めれば良いが、リボ
フラビン酪酸エステル自体を主薬として用いる場合を含
め、得られる目的物に対して約50重量%まで使用でき
る。The amount of the powdered C-type riboflavin butyrate used may be appropriately determined depending on the target product to be produced, but may be up to about 50% by weight based on the obtained target product, including the case where riboflavin butyrate itself is used as the main drug. it can.
本発明における被着色物としては、食品あるいは医薬
品などの分野において使われている原料または一次加工
品(顆粒,裸錠など)を意味する。The coloring object in the present invention means a raw material or a primary processed product (granules, uncoated tablets, etc.) used in the field of food or pharmaceuticals.
また、ハードカプセルやソフトカプセルのシェル部分
にもC型のリボフラビン酪酸エステルを適用することが
できる。Also, C-type riboflavin butyrate can be applied to the shell portion of a hard capsule or a soft capsule.
特に、適用するのに好ましいものとして、固形製剤を
製造する際の原料となる粉末状の薬剤成分を挙げること
ができる。In particular, a powdery drug component serving as a raw material for producing a solid preparation can be preferably used.
このような被着色物としては、例えばアスコルビン
酸,アルコルビン酸ナトリウム,アスコルビン酸カルシ
ウム,ビタミンA,ビタミンD,硝酸チアミン,塩酸ピリド
キシン,ニコチン酸アミド,パントテン酸カルシウム,
ビオチン,ビタミンB12,アセトアミノフェン,臭化水
素酸デキストロメトロファン,アスピリン,メチルエフ
ェドリン,水酸化アルミニウム,酸化マグネシウムのよ
うな薬剤成分、例えばショ糖,ソルビット,マンニッ
ト,デキストロース,サッカリンのような甘味料、例え
ばレモンライム,フルーツエッセンスのようなフレーバ
ー、例えば乳糖,デンプン,結晶セルロース,ヒドロキ
シプロピルセルロース,ヒドロキシプロピルメチルセル
ロース,PVP,カルボキシメチルセルロースカルシウムの
ような賦形剤、例えばステアリン酸マグネシウム,ステ
アリン酸,タルク,軽質無水ケイ酸のような滑沢剤等の
粉末状の固形物ないしそれらの造粒物,成形物などを挙
げることができる。Examples of such coloring materials include ascorbic acid, sodium ascorbate, calcium ascorbate, vitamin A, vitamin D, thiamine nitrate, pyridoxine hydrochloride, nicotinamide, calcium pantothenate,
Pharmaceutical ingredients such as biotin, vitamin B 12 , acetaminophen, dextromethorphan hydrobromide, aspirin, methylephedrine, aluminum hydroxide, magnesium oxide, such as sucrose, sorbitol, mannitol, dextrose, saccharin Sweeteners such as lemon lime, flavors such as fruit essence, excipients such as lactose, starch, microcrystalline cellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, PVP, calcium carboxymethylcellulose, such as magnesium stearate, stearic acid , Talc, powdered solids such as lubricants such as light anhydrous silicic acid, and granulated and molded products thereof.
前述した方法により、被着色物が黄色に着色された着
色物が得られる。この本発明の黄色固体着色物は、その
まま食品あるいは医薬品、たとえば散剤、顆粒剤などの
固形製剤として用いることができる。According to the above-described method, a colored object in which the object to be colored is colored yellow is obtained. The yellow solid color product of the present invention can be used as it is as a solid preparation such as a food or pharmaceutical, for example, a powder or granule.
また、特に黄色造粒物の場合には、これを直接または
他の薬剤と混合して、慣用の錠剤機によって打錠するこ
とにより黄色の錠剤を得ることもできる。In particular, in the case of a yellow granulation, a yellow tablet can be obtained by directly or mixing with another drug and compressing with a conventional tablet machine.
また、糖衣錠,フイルム錠の製造時に、これらの糖衣
液やフィルム液にC型ボフラビン酪酸エステルを添加す
ることによって、着色錠剤を製造することもできる。In addition, a colored tablet can also be produced by adding a C-type boflavin butyrate to a sugar-coated solution or a film solution during production of a sugar-coated tablet or a film tablet.
発明の効果 本発明の黄色固体着色物は、色むらのない明るい鮮や
かなレモン系の黄色を呈すという特徴を有する。Effect of the Invention The yellow solid color product of the present invention has a feature of exhibiting a bright bright lemon-based yellow color without unevenness.
また、口に含んだ際に苦味は感じられず、口中での着
色現象もみられない。In addition, bitterness is not felt when it is contained in the mouth, and no coloring phenomenon in the mouth is observed.
また、本発明の方法では、水性溶媒、例えばエタノー
ル濃度が通常20〜30%のエタノール/水溶媒を使用する
ため、非危険物として取扱うことができる。In the method of the present invention, since an aqueous solvent, for example, an ethanol / water solvent having an ethanol concentration of usually 20 to 30% is used, it can be handled as a non-dangerous substance.
特に、防爆型の造粒機,乾燥機の使用を必要としない
という優れた特徴を有している。In particular, it has an excellent feature that it does not require the use of an explosion-proof granulator or dryer.
また、本発明の黄色固体着色物を用いて他の薬剤成分
と共に加工した錠剤などは色むらの発生がないばかりで
なく、明るいレモン色をそのまま維持しているという特
徴を有している。In addition, tablets and the like processed using the yellow solid coloring material of the present invention together with other drug components not only have no color unevenness but also have a feature that a bright lemon color is maintained as it is.
この錠剤が、例えばビタミン主薬製剤である場合、本
発明の黄色着色物は着色剤としてばかりでなく、主薬と
して配合せしめることができる。When this tablet is, for example, a vitamin-based drug preparation, the yellow colored substance of the present invention can be incorporated not only as a coloring agent but also as a base drug.
以下、実施例を挙げて本発明をさらに具体的に説明す
る。Hereinafter, the present invention will be described more specifically with reference to examples.
実施例で光安定性を示すために用いたハンターの式は
次のようである(“耐候光と色彩",須賀長市著,スガ試
験機出版,昭和52年)。The formula of Hunter used to show light stability in the examples is as follows ("Weathering Light and Color", by Suga Choichi, Suga Test Press, 1977).
ΔE:色差 ΔL:明度差 Δa,Δb:色相差および彩度差 検体をキセノンフェードメーターで10時間照射した時
の、イニシャルからの変化量を、カラーコンピュータSM
−1型(スガ試験機株式会社)を用いて測定し、色差
(ΔE)を算出した。 ΔE: color difference ΔL: lightness difference Δa, Δb: hue difference and saturation difference The amount of change from the initial when the sample was irradiated with a xenon fade meter for 10 hours was calculated using a color computer SM.
The color difference (ΔE) was calculated using a -1 type (Suga Test Instruments Co., Ltd.).
また、実施例中、C型のリボフラビン酪酸エステルの
原料となるリボフラビン酪酸エステルはRTBと表現す
る。In Examples, riboflavin butyrate which is a raw material of C-type riboflavin butyrate is expressed as RTB.
実施例1 黄色に着色された造粒物および錠剤 表1に記載の処方(a)〜(c)に従って、アスコル
ビン酸粉末30重量%を含有する粉糖500gを造粒しながら
着色し、黄色に着色した造粒物を得た(16メッシュ通過
95%)。Example 1 Granules and Tablets Colored in Yellow According to the formulations (a) to (c) described in Table 1, 500 g of powdered sugar containing 30% by weight of ascorbic acid powder was colored while being granulated, and turned yellow. Obtained colored granules (16 mesh passing
95%).
造粒機は、流動層造粒機(FD−3S;非防爆型;富士産
業(株)製)を用い、造粒条件は表2に示す通りであっ
た。The granulator used was a fluidized bed granulator (FD-3S; non-explosion-proof type; manufactured by Fuji Sangyo Co., Ltd.), and the granulation conditions were as shown in Table 2.
さらにこの黄色に着色した造粒物に滑沢剤としてステ
アリン酸マグネシウム(0.7重量%)を加えて混合し、
これを錠剤機(コレクト19K,菊水製作所(株)製)を用
いて打錠して3種の隅角平面錠(a)〜(c)(重量50
0mgl錠,直径10mm)を製造した。Further, magnesium stearate (0.7% by weight) was added as a lubricant to the yellow-colored granules and mixed.
This was tableted using a tablet machine (Collect 19K, manufactured by Kikusui Seisakusho Co., Ltd.) to produce three types of flat corner tablets (a) to (c) (weight: 50).
0mgl tablet, diameter 10mm) was manufactured.
得られた錠剤(a)〜(c)の外観および光安定性
(色素ΔE)を表3に示した。Table 3 shows the appearance and light stability (dye ΔE) of the obtained tablets (a) to (c).
本発明の製造法によれば防爆型の造粒機を用いること
なく、黄色に着色した造粒物、さらにレモン系の明るい
黄色に着色した錠剤を得ることができる。 According to the production method of the present invention, it is possible to obtain a yellow-colored granule and a lemon-based bright yellow-colored tablet without using an explosion-proof granulator.
そして、この錠剤は、色差値が5以下であることか
ら、耐光性において実用上何ら問題を有しない。And since this tablet has a color difference value of 5 or less, it has no practical problem in light fastness.
実施例2 黄色に着色された造粒物および顆粒 アセトアミノフェノン(40重量%)、乳糖(30重量
%)およびデンブン(30重量%)からなる粉末1kgをバ
ーチカルグラニュレーター(FM−VG−10;富士産業
(株)製)に仕込み、これにRTBの懸濁液(RTB0.1gをア
ルコール10mlに溶解したのち、この溶液を水150mlに分
散させ、これにさらにヒドロキシメチルセルロース(3
重量%相当)を加えて調製したもの)を投入して造粒し
ながら着色し、黄色に着色した造粒物を得た。Example 2 Granules and Granules Colored in Yellow 1 kg of a powder consisting of acetaminophenone (40% by weight), lactose (30% by weight) and denbun (30% by weight) was mixed with a vertical granulator (FM-VG-10; The suspension was charged into an RTB suspension (0.1 g of RTB in 10 ml of alcohol), and the resulting solution was dispersed in 150 ml of water.
(Equivalent to weight%) was added, and the mixture was colored while being granulated to obtain a granule colored yellow.
このものを真空乾燥機(楠木製作所(株)製)で乾燥
したあと、パワーミル(P−3;昭和化学機械(株)製)
で整粒し、篩過して16メッシュ通過90%の顆粒を得た。After drying this with a vacuum dryer (Kusunoki Seisakusho Co., Ltd.), a power mill (P-3; Showa Chemical Machinery Co., Ltd.)
The mixture was sieved to obtain 90% granules that passed through a 16 mesh.
なお、比較のため上記粉末1kgにRTB粉末0.1gを単に添
加混合したものについても、水150mlを用いて造粒し、
同様にして顆粒を得た。For comparison, 1 kg of the above powder and 0.1 g of RTB powder simply added and mixed were also granulated using 150 ml of water,
Similarly, granules were obtained.
得られた両顆粒の外観および光安定性を表4に示す。 Table 4 shows the appearance and light stability of the obtained granules.
実施例3 黄色に着色された造粒物および錠剤 アスコルビン酸,アスコルビン酸ナトリウム,ソルビ
トールを主成分とする粉末(アスコルビン酸15重量%、
アスコルビン酸ナトリウム15重量%,ソルビトール60重
量%)10kgを流動層造粒乾燥機(グラットWSQ−15;大川
原製作所(株)製)に仕込み、これをRTBの懸濁液(RTB
20gをエタノール150mlに溶解させ、この溶液を水600ml
に分散させて調製したもの)をスプレーして粉末を造粒
しながら着色した。 Example 3 Granules and tablets colored yellow Ascorbic acid, sodium ascorbate, powder containing sorbitol as a main component (15% by weight of ascorbic acid,
10 kg of sodium ascorbate (15% by weight, sorbitol 60% by weight) was charged into a fluidized bed granulator / dryer (Glat WSQ-15; manufactured by Okawara Seisakusho Co., Ltd.), and this was suspended in RTB suspension (RTB).
Dissolve 20 g in 150 ml of ethanol and add this solution to 600 ml of water
The powder was colored while granulating the powder by spraying.
引き続いて、デンプン100gを水1,900mlに分散させ、8
0℃に加温した糊液をスプレーしながら、さらに造粒し
た。Subsequently, 100 g of starch was dispersed in 1,900 ml of water,
The granules were further granulated while spraying the size liquid heated to 0 ° C.
黄色に着色した造粒物を乾燥して整粒後、実施例1と
同様に打錠して錠剤を製造した。The granules colored yellow were dried and sized, and then tableted in the same manner as in Example 1 to produce tablets.
なお、比較のためRTB20gを単にデンプン糊液600g(デ
ンプン:水=1:19)に分散させた分散液を用いて造粒し
た造粒物を用いて錠剤を製造した。両錠剤の外観および
光安定性は表5の通りであった。For comparison, tablets were produced using granules obtained by granulating using a dispersion obtained by simply dispersing 20 g of RTB in 600 g of starch paste solution (starch: water = 1: 19). Table 5 shows the appearance and light stability of both tablets.
実施例4 黄色に着色された粒状物 結晶グラニウ糖1kgをコーティングパン(12インチ;
菊水製作所(株)製)に仕込み、RTB0.1gをエタノール1
mlに溶解させ、これを水500mlに分散した懸濁液をスプ
レーしながらアスコルビン酸と粉糖との等量混合物(散
布剤)1kgを用いて散布コーティングを行なった。 Example 4 Granules colored yellow Yellow 1 kg of crystalline granulose is coated on a coating pan (12 inches;
Kikusui Seisakusho Co., Ltd.), RTB 0.1g and ethanol 1
The resulting mixture was sprayed with a suspension of 500 ml of water and sprayed with 1 kg of an equal mixture (spray agent) of ascorbic acid and powdered sugar.
粒子の直径が約5mmになるまでコーティングを行な
い、その後真空乾燥(楠木製作所(株)製)し、粒状物
を得た。Coating was performed until the diameter of the particles became about 5 mm, and then vacuum drying (manufactured by Kusunoki Seisaku Co., Ltd.) was performed to obtain granules.
比較のため、RTB0.1gを散布剤1kgに混合したものを用
いて水でスプレーしながら粒状物を製造した。For comparison, granules were produced by spraying with water using a mixture of 0.1 g of RTB and 1 kg of a spray.
得られた両粒状物の外観および光安定性は表6に示す
通りであった。The appearance and light stability of both the obtained granules were as shown in Table 6.
実施例5 黄色に着色された錠剤(糖衣錠) 乳糖およびデンプンを主成分とする粉末(乳糖70重量
%,デンプン30重量%)を打錠して得られた錠剤(直径
9.5mmφ,重量250mg,5,000錠)をコーティングパン(12
インチ;菊水製作所(株)製)中で糖衣掛けを行なっ
た。 Example 5 Yellow-colored tablets (sugar-coated tablets) Tablets (diameter obtained by compression of powder containing lactose and starch as main components (lactose 70% by weight, starch 30% by weight))
9.5mmφ, weight 250mg, 5,000 tablets) coated pan (12
Inch; manufactured by Kikusui Seisakusho Co., Ltd.).
この際、糖衣液は、グラニウ糖,タルク,プルラン,
水からなる糖衣錠1に、RTBの懸濁液(RTB0.1gをエタ
ノール10mlに溶解させ、これを水50mlに分散させたも
の)を添加したものを用いた。At this time, the sugar coating liquid was granulose, talc, pullulan,
A sugar-coated tablet 1 made of water to which a suspension of RTB (0.1 g of RTB dissolved in 10 ml of ethanol and dispersed in 50 ml of water) was added was used.
シロップ液で仕上げを行ない、仕上げ重量450mgの錠
衣錠を得た。Finishing was carried out with a syrup solution to give a tablet with a finished weight of 450 mg.
比較のため、糖衣液にRTB粉末0.1gを単に混合した液
を用いて糖衣掛け、さらにシロップ液で仕上げを行なっ
て糖衣錠を得た。For comparison, a sugar-coated tablet was obtained by sugar-coating using a solution obtained by simply mixing 0.1 g of RTB powder with a sugar-coated solution, and finishing with a syrup solution.
得られた両糖衣錠の外観および光安定性は表7に示す
通りであった。The appearance and light stability of the obtained both sugar-coated tablets were as shown in Table 7.
実施例6 黄色に着色されたフィルム錠 実施例5に記載した乳糖とデンプンの錠剤(直径9.5m
mφ,重量250mg,40,000錠)をアクセラコーター24(マ
ネスティー社製)を用いて、C型のリボフラビン酪酸エ
ステルを含むフイルム液でフイルムコーティングを行な
った。 Example 6 Film tablets colored yellow Yellow lactose and starch tablets (9.5 m diameter) described in Example 5
The film was coated with a film liquid containing C-type riboflavin butyrate by using Axela Coater 24 (manufactured by Monesty Co.) using mφ, weight 250 mg, 40,000 tablets.
使用したフイルム液としては、ヒドロキシプロピルメ
チルセルロース〔TC−5(R);信越化学工業(株)
製〕,酸化チタン,ポリエチレングリコール6000および
水からなるフィルム液3lに、RTBの懸濁液(RTB0.15gを
エタノール1mlに溶解させ、これを水10mlに分散させた
もの)を添加したものを用いた。Examples of the used film liquid include hydroxypropyl methylcellulose [TC-5 (R); Shin-Etsu Chemical Co., Ltd.
3L of a film solution consisting of titanium oxide, polyethylene glycol 6000 and water, and a suspension of RTB (0.15 g of RTB dissolved in 1 ml of ethanol and dispersed in 10 ml of water). Was.
仕上げ重量260mgのフィルム錠を得た。 A film tablet with a finishing weight of 260 mg was obtained.
比較のため、RTB0.15gを単にフイルム液3lに添加した
ものを用いてフイルム錠を製造した。For comparison, a film tablet was produced by simply adding 0.15 g of RTB to 3 l of the film solution.
得られた両フリルム錠の外観および安定性は表8に示
す通りであった。The appearance and stability of both furilm tablets obtained were as shown in Table 8.
実施例7 黄色に着色されたフィルム錠 RTBの懸濁液の代わりに、RTB0.3gをエタノール3mlに
溶解させ、これを水30mlに分散させたものをろ過後、真
空乾燥(楠木機械(株))したC型リボフラビン酪酸エ
ステルの黄色粉末を用いる以外は実施例6と同様に錠剤
のフィルムコーティングを行った。 Example 7 Film tablets colored yellow In place of the suspension of RTB, 0.3 g of RTB was dissolved in 3 ml of ethanol, and this was dispersed in 30 ml of water, filtered, and dried under vacuum (Kusuki Kikai Co., Ltd.) Tablet coating was performed in the same manner as in Example 6 except that the yellow powder of C-type riboflavin butyrate described above was used.
製造されたフィルム錠は、仕上げ重量260mgであっ
た。The manufactured film tablets had a finishing weight of 260 mg.
比較として、RTB0.3gを単にフィルム液3lに添加した
ものを用いて、フィルム錠を製造した。As a comparison, a film tablet was produced using a product obtained by simply adding 0.3 g of RTB to 3 l of the film solution.
得られた両フィルム錠の外観および安定性は表9に示
すとおりであった。The appearance and stability of the obtained film tablets were as shown in Table 9.
実施例8 黄色に着色された糖衣錠 RTBの懸濁液の代わりに、実施例7のRTB黄色粉末と同
じもの1g(実質RTB1g含有)を用いる以外は実施例5と
同様に錠剤の糖衣を行い、糖衣錠を得た。 Example 8 Sugar-coated tablets colored in yellow In place of the suspension of RTB, sugar-coated tablets were prepared in the same manner as in Example 5, except that 1 g of the same RTB yellow powder as in Example 7 (containing 1 g of RTB) was used. Dragee was obtained.
比較として、RTB1gを単に糖衣液1に添加したもの
を用いて、糖衣錠を製造した。As a comparison, a sugar-coated tablet was produced by using one obtained by simply adding 1 g of RTB to the sugar-coated liquid 1.
得られた両糖衣錠の外観および安定性は表10に示すと
おりであった。The appearance and stability of the obtained both sugar-coated tablets were as shown in Table 10.
実施例9 黄色に着色されたハードカプセル ゼラチン30部に水60部を加えて、加熱溶解する。 Example 9 Yellow hard capsules 30 parts of water was added to 30 parts of gelatin and dissolved by heating.
一方、酸化チタン1部と実施例7に記載のRTBの黄色
粉末1部(実質RTB1部含有)を水10部にホモミキサー
(特殊機化(株)製)を用いて、分散したものを作り、
ゼラチン水溶液に加えて着色する。On the other hand, 1 part of titanium oxide and 1 part of the yellow powder of RTB described in Example 7 (containing substantially 1 part of RTB) were dispersed in 10 parts of water using a homomixer (manufactured by Tokushu Kika Co., Ltd.). ,
Add to the aqueous gelatin solution and color.
この溶液にカプセルピンを投入して成型し、乾燥後、
ハードカプセルとする。A capsule pin is put into this solution, molded and dried,
Hard capsules.
得られたカプセルは明るいレモン系の黄色に着色され
ていた。The resulting capsule was colored bright lemon yellow.
試験例 C型リボフラビン酪酸エステルのX線回析 本発明に用いたC型リボフラビン酪酸エステルおよび
RTBをX-ray diffractometer RDA-C型(理学電気製;40k
V,40mA)によりX線回析した結果を第1図および第2図
に示す。Test Example X-ray diffraction of C-type riboflavin butyrate C-type riboflavin butyrate used in the present invention and
RTB to X-ray diffractometer RDA-C type (manufactured by Rigaku Denki; 40k
V, 40 mA) are shown in FIGS. 1 and 2.
本C型リボフラビン酪酸エステルは、“薬学雑誌,10
8(1),39-43(1988)”に記載のC型RTBと同じ、黄色
の微粉末であった。This C-type riboflavin butyrate is described in “Pharmaceutical Magazine, 10
8 (1), 39-43 (1988) ".
また、C型リボフラビン酪酸エステルを得るために用
いたRTBは“薬学雑誌,108(1),39-43(1988)”に記
載のA型リボフラビン酪酸エステルと同じものであっ
た。The RTB used for obtaining the C-type riboflavin butyrate was the same as the A-type riboflavin butyrate described in “Pharmaceutical Magazine, 108 (1), 39-43 (1988)”.
第1図はC型リボフラビン酪酸エステルの粉末X線回析
図である。 第2図はRTBの粉末X線回析図である。FIG. 1 is a powder X-ray diffraction diagram of type C riboflavin butyrate. FIG. 2 is a powder X-ray diffraction diagram of RTB.
Claims (14)
フラビン酪酸エステルで着色してなる黄色固体着色物。1. A yellow solid colored product obtained by coloring a substance to be colored containing a drug component with C-type riboflavin butyrate.
物をC型のリボフラビン酪酸エステルで着色してなる請
求項1記載の黄色固体着色物。2. The yellow solid colored substance according to claim 1, wherein the substance to be colored, which is a powdery or granular drug component, is colored with C-type riboflavin butyrate.
である請求項1記載の黄色固体着色物。3. The yellow solid colored product according to claim 1, wherein the drug component is a component containing ascorbic acid.
酸ナトリウムとを含有する成分である請求項1記載の黄
色固体着色物。4. The yellow solid colored product according to claim 1, wherein the drug component is a component containing ascorbic acid and sodium ascorbate.
のリボフラビン酪酸エステルで着色してなる黄色固体着
色物。5. A yellow solid colored substance obtained by coloring a substance to be colored, which is a capsule or a tablet, with C-type riboflavin butyrate.
セルまたは錠剤である被着色物をC型のリボフラビン酪
酸エステルで着色することを特徴とする着色方法。6. A coloring method comprising coloring a powdered or granular drug component or a substance to be colored, such as a capsule or a tablet, with C-type riboflavin butyrate.
セルまたは錠剤である被着色物を、リボフラビン酪酸エ
ステルのエタノール溶液を水に分散させた懸濁液で着色
することを特徴とする着色方法。7. A coloring method comprising coloring a powdery or granular drug component, or a substance to be colored such as a capsule or a tablet, with a suspension of a riboflavin butyrate ester ethanol solution dispersed in water.
色物の約0.001〜10重量%である請求項7記載の着色方
法。8. The coloring method according to claim 7, wherein the amount of riboflavin butyrate used is about 0.001 to 10% by weight of the material to be colored.
セルまたは錠剤である被着色物を、粉末状のC型のリボ
フラビン酪酸エステルで着色することを特徴とする着色
方法。9. A coloring method comprising coloring a powdery or granular drug component or a substance to be colored, such as a capsule or tablet, with a powdery C-type riboflavin butyrate.
プセルまたは錠剤である被着色物を、請求項7記載の懸
濁液を真空乾燥して得られた粉末状のC型のリボフラビ
ン酪酸エステルで着色することを特徴とする着色方法。10. A powdery or granular drug component or a substance to be colored, such as a capsule or tablet, is colored with a powdery C-type riboflavin butyrate obtained by vacuum-drying the suspension according to claim 7. A coloring method characterized in that:
である請求項6記載の着色方法。11. The coloring method according to claim 6, wherein the substance to be colored is a powdery or granular drug component.
色方法。12. The coloring method according to claim 6, wherein the substance to be colored is a tablet.
がら着色する請求項6記載の着色方法。13. The coloring method according to claim 6, wherein the coloring is performed while granulating the powdery or granular drug component.
て得られる黄色に着色した錠剤。14. A yellow-colored tablet obtained by tableting the yellow solid color product according to claim 2.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP1032373A JP2574176B2 (en) | 1988-02-12 | 1989-02-10 | Yellow solid color |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP3149688 | 1988-02-12 | ||
| JP63-31496 | 1988-02-12 | ||
| JP1032373A JP2574176B2 (en) | 1988-02-12 | 1989-02-10 | Yellow solid color |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH02709A JPH02709A (en) | 1990-01-05 |
| JP2574176B2 true JP2574176B2 (en) | 1997-01-22 |
Family
ID=26369975
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP1032373A Expired - Fee Related JP2574176B2 (en) | 1988-02-12 | 1989-02-10 | Yellow solid color |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2574176B2 (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0876711A (en) | 1994-09-02 | 1996-03-22 | Mitsubishi Electric Corp | Display device |
| CN100430555C (en) * | 2006-04-28 | 2008-11-05 | 张有德 | Steel arch frame folding and unloading device |
| KR100806914B1 (en) * | 2007-02-14 | 2008-02-22 | 경북대학교 산학협력단 | Novel Use of Lipocalin 2 for the Prevention and Treatment of Degenerative Neurological Diseases |
| KR100915790B1 (en) * | 2007-11-23 | 2009-09-04 | 한국원자력연구원 | stress - strain measuring apparatus using bellows structure |
| KR100915789B1 (en) * | 2007-11-23 | 2009-09-04 | 한국원자력연구원 | Stress-strain measuring control method using bellows structure |
| JP2009102328A (en) * | 2008-11-28 | 2009-05-14 | Kokando Pharmaceutical Co Ltd | Solid colored material and medicine |
| JP2019112358A (en) * | 2017-12-25 | 2019-07-11 | 旭化成株式会社 | Cellulose including compact for suppressing separation segregation |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5295698A (en) * | 1976-02-06 | 1977-08-11 | Sadao Mori | Process for preparing liboflavin tetrabutyrate ester |
| JPS613324A (en) * | 1984-06-15 | 1986-01-09 | Matsushita Electric Ind Co Ltd | Optical information recording medium |
| JPS6187620A (en) * | 1984-10-05 | 1986-05-06 | Nisshin Kagaku Kk | Transparent compounded drug preparation of vitamin b2 butyric acid ester for soft capsule |
-
1989
- 1989-02-10 JP JP1032373A patent/JP2574176B2/en not_active Expired - Fee Related
Non-Patent Citations (1)
| Title |
|---|
| 薬学雑誌 第108巻、(1)P.39−43(1988) |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH02709A (en) | 1990-01-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3090730B9 (en) | Tablets comprising eltrombopag olamine | |
| US5215755A (en) | Rotogranulations and taste masking coatings for preparation of chewable pharmaceutical tablets | |
| CA1172167A (en) | Erythromycin base tablets | |
| US4868180A (en) | Vitamin-containing granules and production thereof | |
| US11510909B2 (en) | Pharmaceutical composition of apixaban | |
| EP1300394B1 (en) | Method for the production of a water-dispersible formulation containing carotenoids | |
| KR930001831B1 (en) | Process for the preparation of thiamine salt | |
| US6274168B1 (en) | Phenytoin sodium pharmaceutical compositions | |
| US5320855A (en) | Rotogranulations and taste masking coatings for preparation of chewable pharmaceutical tablets | |
| MXPA02002193A (en) | Delayedaction form of administration containing tramadol saccharinate. | |
| JPH05221854A (en) | Controlling release tablet containing watersoluble chemical | |
| JP6630344B2 (en) | Solid preparation containing colorant | |
| US5767107A (en) | Compositions containing gluten and polysaccharides that contain uronic acid residues useful for encapsulating fats, oils and solids | |
| JP2574176B2 (en) | Yellow solid color | |
| CA2435714C (en) | Fenofibrate tablets | |
| JP2000191516A (en) | Oral solid composition | |
| JPH037230A (en) | Composition of vitamin b group compound and production thereof | |
| JP3333545B2 (en) | Pharmaceutical preparation containing dirithromycin | |
| JPS60255737A (en) | Dihydropyridine composition | |
| JP2008127349A (en) | Solid composition | |
| EP0398033B1 (en) | Oral preparation | |
| CA2118133C (en) | Aminoguanidine spray drying process | |
| EP0328129B1 (en) | Yellow-colored solid matter and production thereof | |
| JP2000016940A (en) | Composition containing vitamins b12 | |
| JPS60255736A (en) | Nifedipine preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20071024 Year of fee payment: 11 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20081024 Year of fee payment: 12 |
|
| LAPS | Cancellation because of no payment of annual fees |